TY  - JOUR
TI  - Evaluation of plasma carnitine status in patients diagnosed with juvenile idiopathic
arthritis
AB  - Background/aim: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood and manifests mainly as
autoinflammation of the joints and other tissues. Several treatment options such as nonsteroidal antiinflammatory drugs, methotrexate,
and intra-articular steroids are widely used to relieve and improve this inflammation. Secondary carnitine deficiency can be detected in
chronic diseases by either renal loss or increased demand. While carnitine status can be associated with several conditions, in the present
study our aim is to determine the levels of free carnitine and acyl-carnitine in Turkish JIA patients.
Materials and methods: One hundred and fourteen patients diagnosed with juvenile idiopathic arthritis and 50 healthy individuals
who served as the control group were included in the study. A fasting blood sample was collected from the children in both groups to
determine free carnitine and acylcarnitine ester by quadripole electrospray tandem mass spectrometry (ESI-MS/ MS).
Results: Screening of acyl-carnitine profile revealed free carnitine, C14, C14:2, C16, C16-OH, and C18 carnitine levels were higher (p
< 0.0001, p < 0.0001, p < 0.001, p < 0.001, and p = 0.011, respectively), while C2, C3, C4, C6, C8, C10, C10:1, C10:2, C3DC, C4DC,
C5DC, C4-OH, and C18:1-OH carnitine levels were lower (p < 0.0001) in JIA patients in comparison to the control group. Total acylcarnitine levels (p < 0.001) and acyl-carnitine to free carnitine ratio (p < 0.001) were also lower in JIA patients than the control group.
Free carnitine levels were significantly higher (48.05 ± 13.36 μmol/L) in patients under antiinflammatory drug therapy than those who
did not receive any treatment (43.18 ± 7.96 μmol/L) (p = 0.004).
Conclusion: In the present study we were not able to define secondary carnitine deficiency in JIA patients, although free carnitine and
acyl-carnitine variations were detected in JIA patients. In conclusion, routine carnitine supplementation is not recommended in all
patients with JIA.
AU  - KIYKIM, Ertuğrul
AU  - Zubarioglu, Tanyel
AU  - Aktuglu Zeybek, Ayse Cigdem
AU  - Barut, Kenan
AU  - Kasapcopur, Ozgur
AU  - cansever, mehmet şerif
DO  - 10.55730/1300-0144.5366
PY  - 2022
JO  - Turkish Journal of Medical Sciences
VL  - 52
IS  - 3
SN  - 1300-0144
SP  - 724
EP  - 729
DB  - TRDizin
UR  - http://search/yayin/detay/536401
ER  -